233.24

3.90% 8.765

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $233.24, with a volume of 715.89K. It is up +3.90% in the last 24 hours and down -2.11% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Previous Close:

$224.47

Open:

$230

24h Volume:

715.89K

Relative Volume:

0.54

Market Cap:

$31.21B

Revenue:

$4.29B

Net Income/Loss:

$577.22M

P/E Ratio:

55.42

EPS:

4.2086

Net Cash Flow:

$641.34M

1W Performance:

+3.88%

1M Performance:

-2.11%

6M Performance:

-30.04%

1Y Performance:

-50.40%

1-Day Range:

$228.12

$234.05

1-Week Range:

$221.56

$233.60

52-Week Range:

$197.81

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,500

Twitter

@alnylam

Next Earnings Date

2026-10-29

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	233.24	31.21B	4.29B	577.22M	641.34M	4.2086
VRTX Vertex Pharmaceuticals Inc	509.74	129.20B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.40	95.18B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.26	82.49B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	849.01	53.39B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.37	42.01B	5.76B	514.49M	1.10B	4.4813

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-26	Initiated	BMO Capital Markets	Outperform
Aug-03-26	Upgrade	Raymond James	Outperform → Strong Buy
May-19-26	Initiated	Citigroup	Buy
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Jan-28-26	Resumed	Barclays	Overweight
Jan-07-26	Resumed	Oppenheimer	Outperform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

Oct 12, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research

Oct 12, 2026

Oct 09, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research

Oct 09, 2026

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research

Oct 09, 2026

Oct 08, 2026

Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research

Oct 08, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research

Oct 08, 2026

Oct 07, 2026

ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research

Oct 07, 2026

Oct 06, 2026

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research

Oct 06, 2026

Oct 05, 2026

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Oct 05, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.

Oct 05, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - wboc.com

Oct 02, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire

Oct 02, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire Inc.

Oct 02, 2026

An Alnylam (ALNY) officer proposes a $399K share sale that includes shares to cover an equity-award tax bill. - Stock Titan

Oct 02, 2026

Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - Simply Wall Street

Oct 02, 2026

Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - simplywall.st

Oct 02, 2026

Oct 01, 2026

Alnylam Shares Fall as Investors Weigh Earlier 2026 Outlook Reset Against a Near-Term Data Wait - Quiver Quantitative

Oct 01, 2026

Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - benzinga.com

Oct 01, 2026

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail

Oct 01, 2026

Sep 30, 2026

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Stock Forecast & Analyst Predictions - simplywall.st

Sep 30, 2026

Alnylam Pharmaceuticals (ALNY) Stock Forecast and Price Target 2026 $ALNY - MarketBeat

Sep 30, 2026

Sep 29, 2026

A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. - Stock Titan

Sep 29, 2026

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - Times Argus

Sep 29, 2026

Sep 28, 2026

Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - NAI500

Sep 28, 2026

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha

Sep 28, 2026

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance

Sep 28, 2026

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView

Sep 28, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Yahoo Finance

Sep 28, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool

Sep 28, 2026

Sep 27, 2026

Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 26, 2026

Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha

Sep 26, 2026

Sep 25, 2026

Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO - The Business Journals

Sep 25, 2026

The next Alnylam? RNAi biotech City Therapeutics files for IPO - Endpoints News

Sep 25, 2026

Sep 22, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 22, 2026

Sep 21, 2026

Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates - Eastern Progress

Sep 21, 2026